|
Home
>
Newsletters
>
Devices & Diagnostics Letter
> Misleading Imagery in Alzheimer’s PET Drug Lands Untitled Letter
Devices & Diagnostics Letter
Sept. 17, 2012
| Vol.
39 No.
37
Misleading Imagery in Alzheimer’s PET Drug Lands Untitled Letter
Eli Lilly has misbranded its radioactive PET drug Amyvid, approved for reviewing displays of brain scans using a black-and-white scale, by featuring a multi-colored brain image on a web page advertisement and other promotional materials for the product, according to an FDA untitled letter.
|
|
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews
All rights reserved. Do not duplicate or redistribute in any form.